Ms. Anne Whitaker was appointed as a non-executive director of ICON plc in July 2024. 

Ms. Whitaker is an experienced executive with more than 30 years of experience in the life seciences industry across large pharmaceutical, biotech, and specialty pharmceutical companies. Ms. Whitaker has extensive leadership experience, having been CEO for three clinical- stage biotech businesses (Aerami Therapeutics, Synta Pharmaceuticals and Novovlem Therapeutics) complemented by substantial bigger pharma - most notably Bausch Health, Sanofi, and GSK.Ms. Whitaker held senior executive commerical roles with GSK at a local US and global levels and was responsible for running Sanofi's North America operations. 

Ms. Whitaker serves as the Chair of QurAlis and as a non-executive director of Telix Pharmaceuticals, Trinity Life Sciences, Byrn Pharma, Bespak, and is a Member of the Board of Trustees of the University of North Alabama. Ms. Whitaker previously served on the boards of Curio Digital Therapeutics, Ergomed plc, UDG Healthcare, Cree, Mallinckrodt, KNOW Bio, Novoclem Therapeutics, Vectura Group and Synta Pharmaceuticals and Nykode Therapeutics. Ms. Whitaker holds a BSc in Chemistry and Business from the University of North Alabama. 

Ms. Whitaker holds a BSc in Chemistry and Business from the University of North Alabama.